Posterior juxtascleral injection of anecortave acetate - Magnetic resonance and echographic imaging and localization in rabbit eyes
Posterior juxtascleral injection of anecortave acetate - Magnetic resonance and echographic imaging and localization in rabbit eyes
复制标题
DOI：
10.1097/01.iae.0000242853.80913.63
复制
发表时间：
2007-02-01
影响因子：
3.3
通讯作者：
Moshfeghi, Andrew A.
中科院分区：
文献类型：
--
作者：
Jockovich, Maria-Elena;Murray, Timothy G.;Moshfeghi, Andrew A.
目的：通过眼部成像技术确定药物在兔眼的巩膜旁给药，并确定药物的定位和分布随时间的变化。方法：4只雌性新西兰大白兔，体重2.5~3.0 kg，单次巩膜旁后Tenon囊袋内注射0.5mL或1mL30 mg/mL安可达。分别于注药前、注药后即刻、注药后2小时、1周、4周对兔眼进行超声和核磁共振成像。结果：超声和MRI显示，巩膜旁后Tenon囊下注射Anecortave醋酸酯能有效地将药物直接对准兔眼后极部。药物在巩膜旁至少停留了5周。注射后即刻MRI可清晰显示药物，此后强度降低。实时超声分析清楚地显示了插管和给药过程。注射药物后即刻，超声检查间接定位乙酸乙酯回声透明带位于巩膜表面后方。但在以后的时间点，超声检查证实药物在巩膜旁的位置是同一位置的相对回声灶。结论：经后Tenon囊下入路巩膜旁给药有效地将药物直接对准眼球后方的所需位置。核磁共振和超声检查均显示，在首次注射后，安可他韦仍在此部位定位至少5周。
Purpose: To confirm juxtascleral delivery of anecortave acetate in rabbit eyes by ocular imaging techniques and to determine drug localization and distribution as a function of time after injection.Methods: Four female New Zealand white rabbits (weight, 2.5-3.0 kg) received a single juxtascleral posterior sub-Tenon capsule injection of 0.5 mL or 1 mL of 30 mg/mL anecortave acetate. Rabbit eyes were imaged with ultrasonography and magnetic resonance imaging (MRI) before injection, immediately after injection, and at 2 hours, 1 week, and 4 weeks after injection. Rabbit eyes were also imaged with b-mode ultrasonography during the juxtascleral injections.Results: Ultrasonography and MRI demonstrated that juxtascleral posterior sub-Tenon capsule injection of anecortave acetate effectively delivered the drug in direct apposition to the posterior pole of the rabbit eye. The drug remained in the juxtascleral site for at least 5 weeks. The drug was visualized clearly by MRI immediately after injection, decreasing in intensity thereafter. Cannula insertion and the drug delivery process were clearly visualized by real-time ultrasound analysis. Immediately after drug injection, ultrasonography indirectly localized anecortave acetate localization as an echolucent zone posterior to the scleral surface. At the later time points, however, the juxtascleral location of the drug was verified with ultrasonography as a relatively echogenic focus in the same location.Conclusions: Juxtascleral administration of anecortave acetate via a posterior subTenon capsule approach effectively delivered the drug to the desired position in direct apposition to the globe posteriorly. MRI and ultrasonography both demonstrated that anecortave acetate remained localized to this location for at least 5 weeks after initial injection.